Cargando…
Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
Iron deficiency anemia (IDA) is a leading global health concern affecting approximately 30% of the population. Treatment for IDA consists of replenishment of iron stores, either by oral or intravenous (IV) supplementation. There is a complex bidirectional interplay between the gut microbiota, the ho...
Autores principales: | Rieg, Timo, Xue, Jianxiang, Stevens, Monica, Thomas, Linto, White, James R., Dominguez Rieg, Jessica A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520285/ https://www.ncbi.nlm.nih.gov/pubmed/37671923 http://dx.doi.org/10.1042/BSR20231217 |
Ejemplares similares
-
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022) -
Intravenous ferric derisomaltose for the treatment of iron deficiency anemia
por: Auerbach, Michael, et al.
Publicado: (2021) -
Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
por: Emrich, I. E., et al.
Publicado: (2020) -
Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
por: Bombač Tavčar, Lea, et al.
Publicado: (2023) -
An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
por: Pollock, Richard F, et al.
Publicado: (2021)